First allosteric insulin receptor-activating antibody to improve glycemic control in vivo

XOMA Corporation (Nasdaq: XOMA) announced that its study of XMetA, the company’s fully-human allosteric monoclonal antibody to the insulin receptor, is available online and will be published in the May issue of the American Diabetes Association’s journal Diabetes.

Read more

Posted in Drugs